Stocks soar on hopes of Iran war resolution — plus, Lilly takes a big swing in sleep disorders

The S&P 500 rallied more than 2% on unconfirmed reports of potential de‑escalation in Iran; WTI crude eased ~1% but remained above $100/bbl. Eli Lilly announced an acquisition of Centessa Pharmaceuticals worth up to $7.8 billion for cleminorexton, which Wolfe Research forecasts could exceed $3 billion in peak sales if successful—analysts view the deal as positive for Lilly's neuroscience exposure. Truist initiated Corning with a hold and $125 target citing optical momentum but high valuation; Nike reports after the close and macro data (ADP private payrolls, February retail sales, ISM manufacturing) are due, while tariffs and GLP‑1 competitive dynamics (Novo Nordisk subscription pricing) are noted risks.

Analysis

Recent headlines that reduce a geopolitical risk premium will likely compress oil-linked volatility over weeks-to-months, not permanently. Mechanically, a persistent decline in the risk premium reduces working capital stress for refiners and provides a 3–7% tailwind to airline and transport operator margins for every $5/bbl fall sustained over a quarter; the reverse can flip within 48–72 hours if tensions spike again.

The biotech M&A cadence is shifting capital from high-BU clinical risk into strategic platform buys; that raises takeover optionality for small, de-risked neuroscience assets and lifts adjacent service providers (CROs, specialty CDMOs, royalty financiers) as acquisition partners. Expect a two- to twelve-month window where acquisition comps re-price a cohort of sub-$1.5bn market-cap developers, compressing volatility for targets but expanding downside for those missing lead-indication readouts.

Optical/data-center dynamics are entering a structural upgrade phase: hyperscaler co-investment in silicon photonics raises optical spend per rack by an estimated 10–15% over 12–24 months, favoring incumbents in glass/fiber and module assembly while exposing commodity passive suppliers to margin pressure. This increases asymmetric upside for select optical suppliers but leaves semiconductor capital equipment exposed to cyclic cut risk if macro capex stalls.

Near-term corporate catalysts (payroll/retail prints, select earnings) create 3–8% single-session directional moves; for consumer names with China exposure, tariffs and distribution changes remain the dominant 6–18 month risk. Markets are pricing optimism but remain fragile to headline-driven regime flips — position sizing and volatility-aware structures are essential.

Key Decisions for Investors

• Long CNTA equity or Jan-2027 LEAP calls (12–18 month horizon): position size 2–4% portfolio. Rationale: M&A optionality in de-risked neuroscience cohort; target +40–60% upside on a successful strategic process or positive clinical readouts. Risk: binary clinical/M&A failure; cap downside by buying calls or using a 3:1 risk cap (max loss = premium paid).
• Long GLW (optical incumbent) on an 8–12% pullback, 6–12 month horizon: target +25–35%; stop-loss -12% from entry. Rationale: accelerating silicon-photonics-driven spend and hyperscaler co-investment favor glass/module suppliers. Risk: macro capex cut that delays projects — hedge with short-dated put options if tech capex data deteriorates.
• Long NVDA LEAP calls (12–24 months) funded partially by selling 3–6 month covered calls or call spreads: target ~2.5x return if data-center optical adoption accelerates; downside limited to premium minus premium received. Rationale: strategic partnerships are early signal of sustained optical content per GPU rack. Risk: sharp GPU cycle pullback or share-based dilution; use collars to cap drawdown.
• Tactical short NKE via a 3–5 week put spread into earnings (earnings event hedge): small allocation (0.5–1%); scenario: buy put 1 and sell put 2 to keep max loss = premium. Rationale: asymmetric downside if China and tariff headlines disappoint relative to muted consensus. Reward: potential 3–5x payoff from an earnings-driven vol spike; risk limited to premium paid.